オプションチェーンは、Rani Therapeutics Hldgsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Rani Therapeutics Hldgsの市場センチメントを評価します。.

Rani Therapeutics Hldgs (NASDAQ:RANI) 株価情報, オプションチェーン

RANI THERAPEUTICS HOLDINGS-A

Rani Therapeutics Hldgs

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Holdings Inc

Canaccord Genuity analyst Michael Walkley maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Hold and lowers the price target from $43 to $39.

News

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on Rapid7, Lowers Price Target to $39

Stifel analyst Jim Duffy maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Buy and lowers the price target from $11 to $10.

Stifel Maintains Buy on Under Armour, Lowers Price Target to $10

Smartphone makers like Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) are hoping that consumers will trade in their phones for <a href="https://www.benzinga.com/tech/25/04/44850406/apples-foldable-iphone-rumors-gain-steam-as-stock-slides-could-a-2000-device-spark-a-comeback">new ones in the next year</a>, an item that could lock in additional revenue and higher margins.
A new Benzinga poll finds that the percentage of people who have upgraded their phones in the last 12 months is below 50%.
What Happened: Analysts highlight that users upgrading their Apple iPhones could help the technology giant boost <a href="https://www.benzinga.com/news/earnings/25/05/45152493/apple-reports-strong-q2-earnings-revenue-beat-eps-beat-installed-base-hits-all-time-high-across-all-segments-100-billion-buyback-and-more">its annual revenue</a> after releasing the iPhone 16 in September 2024 and getting ready to release the iPhone 17 in the future.
Benzinga polled readers to find out where they stand in the upgrade cycle.
"Which of the following describes your smartphone currently?" Benzinga asked.
Here were the results:
<ul class="wp-block-list">
<li>I own an iPhone and have not gotten a new phone in the last 12 months: 38%</li>
<li>I own an iPhone and got a new phone in the last 12 months: 22%</li>
<li>I own a different smartphone and have gotten a new phone in the last 12 months: 17%</li>
<li>I own a different smartphone and have not gotten a new phone in the last 12 months: 15%</li>
<li>I don't own a smartphone: 8%</li>
</ul>
The poll found that 53.5% of consumers have not upgraded their smartphones in more than 12 months, or an even higher percentage if stripping out the 8% who answered that they don't own a smartphone. The poll found that 38.6% of respondents have upgraded their smartphones in the last 12 months.
Another important finding in the poll was the strong brand power that Apple commands, with 60.4% of the users answering the question saying they own an iPhone.
Read Also: <a href="https://www.benzinga.com/tech/25/05/45357613/china-tariff-de-escalation-biggest-winners-include-tesla-apple-new-tech-highs-back-on-the-table-now-for-2025">China Tariff De-Escalation Biggest Winners Include Tesla, Apple: &#8216;New Tech Highs Back On The Table Now For 2025&#8217;</a>
Why It's Important: The fact that over 50% of users said they have not upgraded their smartphone in more than 12 months could bode well for Apple in the next iPhone release cycle.
Also potentially helping Apple would be the growth of AI features like Apple Intelligence with the iPhone 17. Apple Intelligence released in October 2024, a month after the iPhone 16 released.
While users could upgrade to experience Apple Intelligence, the full benefits of an upgrade cycle may not have been realized by Apple and could be hit with a new iPhone that comes standard with Apple Intelligence features.
Benzinga also asked users which feature is the most important when considering a phone upgrade.
"Which of the following is the most important reason to upgrade to a new phone?" Benzinga asked.
The results were:
<ul class="wp-block-list">
<li>Old phone feels outdated: 28%</li>
<li>Artificial intelligence features: 27%</li>
<li>Better battery life: 26%</li>
<li>Batter camera: 19%</li>
</ul>
The poll found that an outdated phone, which could mean a number of things, is the most important factor when considering an upgrade. Ranking second could be the key for Apple's future success with artificial intelligence features the second-most important reason to upgrade a smartphone.
The study was conducted by Benzinga from May 5, 2025, through May 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 316 adults.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/04/45112477/exclusive-if-meta-is-forced-to-divest-instagram-whatsapp-or-facebook-43-pick-this-standout">EXCLUSIVE: If Meta Is Forced To Divest Instagram, WhatsApp, Or Facebook, 43% Pick This Standout</a></li>
</ul>

Exclusives

Tech

Trading Ideas

AAPL

EXCLUSIVE: Apple Stock Could Benefit From Smartphone Upgrade Cycle, Poll Ranks Top Reason For Trade In (It's Not The Camera)

<a href="https://www.benzinga.com/news/25/04/44590350/courtroom-clash-no-thank-you-sparks-lawsuit-as-altman-shuts-down-musks-97-4b-bid">Elon Musk </a>is setting the stage for what could be one of the artificial intelligence industry&#8217;s biggest financial leaps. During a recent investor update on April 21, first shared with <a href="https://www.youtube.com/watch?v=XH5O_X1xG2o">CNBC</a>, Musk said he wants to assign a &#8220;proper value&#8221; to his AI startup, xAI.&nbsp;
He didn't confirm a new fundraising round, but his comment hinted at possible funding from Middle Eastern sovereign wealth funds and global investors, according to people familiar with the matter. This comes after xAI secured $6 billion in late 2024, giving the company a $50 billion valuation, <a href="https://www.forbes.com/sites/antoniopequenoiv/2024/12/23/xai-valuation-reaches-over-40-billion-after-6-billion-funding-round/">Forbes reported</a>.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
<h2 class="wp-block-heading">A Big Bet On AI Infrastructure</h2>
The $6 billion raise wasn&#8217;t for buzz—it powered the expansion of &#8220;Colossus,&#8221; xAI&#8217;s supercomputer in Memphis.&nbsp;
Colossus is built with 100,000 Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) H100 GPUs and was designed to train xAI&#8217;s large language model, Grok, and is seemingly one of the most powerful AI clusters to date.
Musk&#8217;s ambitions don&#8217;t end there. As reported by the <a href="https://www.ft.com/content/53eeadd8-8fec-4f1b-991e-642e24959e02">Financial Times</a>, Musk already has plans to deploy more than 1 million GPUs, which will require scaling up Colossus. The additional capacity would give xAI a significant edge in the generative AI race, putting it in competition with established players like OpenAI and Anthropic.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
Meanwhile, in March, xAI finalized a $33 billion all-stock merger with Musk&#8217;s other venture, X. The combination integrates xAI&#8217;s technology with X&#8217;s social media ecosystem. Musk said in an <a href="https://x.com/elonmusk/status/1905731750275510312?lang=en">X post</a> that the move will provide smarter, and more meaningful experiences to billions of people.
It also solidifies xAI's revenue stream, which industry intelligence platform <a href="https://sacra.com/c/xai/">Sacra</a> estimates at about $100 million annually, primarily from X Premium subscriptions and API services.
After the merger, Musk<a href="https://x.com/elonmusk/status/1905731750275510312"> posted on X</a>, &#8220;This combination will unlock immense potential by blending xAI&#8217;s advanced AI capability and expertise with X&#8217;s massive reach.&#8221; ​His goal? To streamline AI into everyday digital interactions.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Another layer of potential investment surfaced in July. After running a public<a href="https://x.com/elonmusk/status/1815907844434112999?s=46=PySpYjNmRDrcisnq5IFhJQ"> poll on X</a>, Musk proposed bringing a $5 billion investment from Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) into xAI to the automaker&#8217;s board.&nbsp;
The poll revealed that 67.9% of voters supported the idea of Tesla investing $5 billion in his artificial intelligence startup, xAI. The initiative could link xAI&#8217;s capabilities directly to Tesla&#8217;s self-driving software and in-vehicle AI systems.
Looking forward, Bloomberg reported that <a href="https://www.benzinga.com/news/25/04/44725803/musks-xai-aims-for-1-million-gpus-in-memphis-but-can-the-citys-grid-handle-a-27b-ai-power-surge">xAI</a> is <a href="https://www.bloomberg.com/news/articles/2025-02-14/musk-s-xai-discussing-10-billion-raise-at-75-billion-valuation">seeking </a>to raise an additional $10 billion, potentially pushing its valuation to $75 billion. the funding goal in February and would place xAI in the same financial orbit as top AI labs.
Read Next:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
Image: Shutterstock

NVDA

TSLA

Elon Musk Wants A 'Proper Value' For xAI — After $6 Billion Raise, 100,000 GPUs, And A Quiet $100 Million Deal Most Missed

WIIM

CINT

CINT stock has given up its prior loss. CI&T shares were trading lower after the company reported worse-than-expected Q1 financial results.

Stifel analyst Jim Duffy maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and raises the price target from $57 to $66.

ONON

Stifel Maintains Buy on On Holding, Raises Price Target to $66

Canaccord Genuity analyst Austin Moeller maintains Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a Buy and raises the price target from $21 to $21.5.

LUNR

Canaccord Genuity Maintains Buy on Intuitive Machines, Raises Price Target to $21.5

GSIW

Garden Stage Shares Halted On Circuit Breaker To The Upside, Stock Now Up 69%

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 10.51% on an annualized basis producing an average annual return of 25.53%. Currently, Cencora has a market capitalization of $54.16 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $313.24 today based on a price of $279.60 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747237519_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Stifel analyst Stephen Willey maintains Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) with a Hold and lowers the price target from $6 to $5.

MGNX

Stifel Maintains Hold on Macrogenics, Lowers Price Target to $5

Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) with a Buy and raises the price target from $32 to $43.

GRAL

Canaccord Genuity Maintains Buy on GRAIL, Raises Price Target to $43

RBC Capital analyst Keith Mackey maintains Trican Well Service (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TCW#TSX">TCW</a>) with a Outperform and raises the price target from C$5.5 to C$6.

TSX:TCW

RBC Capital Maintains Outperform on Trican Well Service, Raises Price Target to C$6

Stifel analyst J. Bruce Chan maintains Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) with a Hold and lowers the price target from $147 to $140.

LSTR

Stifel Maintains Hold on Landstar System, Lowers Price Target to $140

Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and lowers the price target from $75 to $70.

ENOV

Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $70

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) with a Buy and lowers the price target from $2.5 to $1.5.

BDSX

Canaccord Genuity Maintains Buy on Biodesix, Lowers Price Target to $1.5

Health In Tech Shares Resume Trade

<a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-secures-historic-1-2-trillion-economic-commitment-in-qatar/" title="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-secures-historic-1-2-trillion-economic-commitment-in-qatar/">https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-secures-historic-1-2-trillion-economic-commitment-in-qatar/</a>

Contracts

Global

Trump Secures Historic $1.2T Economic Commitment In Qatar; Deals With Qatar Include More Than $243B, Including Sale Of Boeing Aircraft And GE Aerospace Engines To Qatar Airways; Qatar Airways To Acquire 210 Boeing 787 Dreamliner And 777x Aircraft Powered By GE Aerospace Engines; Raytheon Secures $1B Agreement For Qatar Acquisition Of Counter-Drone Capabilities; General Atomics Secured A Nearly $2B Agreement For Qatar's Acquisition Of The MQ-9B Remotely Piloted Aircraft System

Susquehanna analyst Christopher Rolland maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Neutral and raises the price target from $100 to $110.

SLAB

Susquehanna Maintains Neutral on Silicon Laboratories, Raises Price Target to $110

RBC Capital analyst Ken Herbert maintains Karman Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) with a Outperform and raises the price target from $38 to $44.

KRMN

RBC Capital Maintains Outperform on Karman Holdings, Raises Price Target to $44

Susquehanna analyst James Friedman maintains PagSeguro Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAGS#NYSE">PAGS</a>) with a Positive and lowers the price target from $16 to $14.

PAGS

Susquehanna Maintains Positive on PagSeguro Digital, Lowers Price Target to $14

Press Releases

"Peraso Inc. (NASDAQ: PRSO) Revolutionizes Consumer Experiences with Game-Changing mmWave Technology" more stocks inside….

Health Care

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Rani Therapeutics to Participate in Upcoming Investor Conferences

Earnings

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

General

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

BNZI

BREA

DRUG

ILLR

NIVF

NIXX

PRSO

RANI

STAF

TVGN

VMAR

VSME

XPON

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Comments

Rani Therapeutics Hldgs

Rani Therapeutics Hldgs (RANI) オプション

Rani Therapeutics Hldgs (NASDAQ:RANI) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル